Sun, Dec 21, 2014, 11:00 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Zynga, Inc. Message Board

pharmaapproved 249 posts  |  Last Activity: 7 hours ago Member since: Jun 7, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • pharmaapproved pharmaapproved Dec 3, 2014 5:58 PM Flag

    Biopharmcatalyst/FDAcalander

    Important: Note the catalyst date is the "Latest" expected date for the catalyst to occur.
    For Example, if the catalyst says 12/31/2014, it does not necessarily mean the catalyst will occur on this date. In "MOST" cases it will occur before the date.

    Ticker ETRM 12/31/2014

  • Reply to

    Why FDA Approval Is Probable

    by dctrig Dec 3, 2014 2:11 AM
    pharmaapproved pharmaapproved Dec 3, 2014 11:41 AM Flag

    So some say. But listen to the wording "Finalizing the label with the FDA" that sounds to me the FDA is working with them on the label, The FDA isn't going out of it's way for no reason are they?

  • Reply to

    Why FDA Approval Is Probable

    by dctrig Dec 3, 2014 2:11 AM
    pharmaapproved pharmaapproved Dec 3, 2014 8:09 AM Flag

    That and "Finalizing the label with FDA" wouldn't make much sense to be "Finalizing" anything if you weren't going to approve the device!

  • pharmaapproved by pharmaapproved Dec 2, 2014 2:43 PM Flag

    There was someone with 4000+ followers who flocked in last week or the week before. Anyway, the point I'm making is there are many of them who will be selling at break-even or even a loss. Why, because their "traders" looking for fast $$$. When they don't see any action in a very short amount of time they move on. There's nothing wrong with that, I just thought i'd point out what I think we're seeing.

    Selling your shares with a market sell order is foolish imo. As soon as they clear out we will see our next leg up! Don't get scared now & hold onto them shares! Christmas may come early this year!!!

  • Reply to

    Australia

    by flythink222 Dec 1, 2014 1:33 PM
    pharmaapproved pharmaapproved Dec 1, 2014 5:12 PM Flag

    I have a different theory so how about this. We've been told all along that they're in talks with potential EU/AU partners. What do these potential partners really want? The U.S.? That's what I think and ETRM surly know they have a much more valuable company with FDA approval. ETRM has financially played it the best they could have without having to sign an early partnership deal. Thus there was little concentration on the EU/AU because they knew they would need drain the accounts to focus on reimbursement in these countries. But no they focused on U.S. approval to only let the rest play itself out over time. IMO there are already interested parties but ETRM is not giving the company away before a U.S. decision!

  • Reply to

    Australia

    by flythink222 Dec 1, 2014 1:33 PM
    pharmaapproved pharmaapproved Dec 1, 2014 3:49 PM Flag

    Nice to see not all have forgotten the possibilities in Australia. We seem to forget there's much more going on beyond FDA approval. Already approved for obesity in Australia. Now working on a few issues and sales could come within the next few quarters per ETRM. EU still on track with discussions progressing surrounding obesity & diabetes with their already approved device.

  • Reply to

    PPS

    by murfee69 Dec 1, 2014 10:40 AM
    pharmaapproved pharmaapproved Dec 1, 2014 11:53 AM Flag

    Inns, the point i'm trying to make is hopefully a shift from people believing strictly in drug companies to devices. From everything I read that is a real possibility until they make drugs without harmful side effects. Less invasive surgery - No Pills = VBLOC

  • Reply to

    PPS

    by murfee69 Dec 1, 2014 10:40 AM
    pharmaapproved pharmaapproved Dec 1, 2014 11:41 AM Flag

    300,000 out of 20M "opt" for surgery.

    I posted a thread over the weekend "Obesity – A Growing Opportunity for the Med-Tech Industry 25 Nov 2014"

    "On the other hand, while current bariatric surgery techniques have demonstrated notable improvements in safety and efficacy compared with years prior, patient aversion to surgical intervention has curbed operation prevalence to less than 1% of suitable obese candidates. In the US alone, of the 20 million Americans that qualified for bariatric surgery in 2012, only 200,000 opted for the surgery."

  • Reply to

    approval

    by steelhead111222 Dec 1, 2014 9:10 AM
    pharmaapproved pharmaapproved Dec 1, 2014 11:25 AM Flag

    I think I see sarcasm.

  • Reply to

    PPS

    by murfee69 Dec 1, 2014 10:40 AM
    pharmaapproved pharmaapproved Dec 1, 2014 11:21 AM Flag

    I think you're right as far as early expectations by some. I see better than $2 though with approval, I basically see a value of about $300M or so within days/weeks of approval. I base this on nothing more than what the market is pricing stocks in the obesity field. I think with the 20M people each year who qualify for surgery and yet refuse to are looking for something not so drastic. These same 20M people also refuse to take pills from past experience. So we have 20M people each year who refuse to have their guts ripped apart, altered, and refuse pills. Enter VBLOC less invasive with no harmful side effects. The WW $$$$ potential is huge in the right hands!!!

  • pharmaapproved pharmaapproved Nov 30, 2014 11:02 AM Flag

    bohemiansummitDOTcom/assets/docs/bohemianagendaDOTpdf

  • pharmaapproved pharmaapproved Nov 29, 2014 4:43 PM Flag

    No mention of EnteroMedics, more for the heavy hitters in the space where several are mentioned. As far as the centers, like we've talked about before the centers surgeons ect... will be doing most of the selling for us. It starts with 13 and grows from there. Throw in some upcoming surprises out of the EU and Australia and watch the on lookers on the sidelines start believing!

  • pharmaapproved pharmaapproved Nov 29, 2014 3:36 PM Flag

    You never know it could be. I'm hoping we get a decision this week. From the little I can find on timelines the 5th of each month seems to stick out. So maybe Friday, but that's just a guess.

  • pharmaapproved pharmaapproved Nov 29, 2014 3:33 PM Flag

    YES, even better.

  • Clinical Spotlight – Metabolic/Diabetes
    The number of people diagnosed with type 2 diabetes and obesity is growing fast and the trend is projected to continue. While pharmaceutical treatments are facing huge challenges in terms of developing safe and effective drugs, medical devices are playing an increasingly important role in both prevention and treatment, especially through drug delivery devices for insulin and more recently through temporary implantables that look to have a significant effect on both obesity and diabetes. In this session, industry executives and physicians will talk about the devices that provide simple and less-invasive technologies that will not only manage the disease’s symptoms but may reverse them.
    ------------------------------------------------------------------------------------------------------
    The Strategic Perspective — Reading the M&A Landscape
    The endgame in medical devices today, from both a small company and big company perspective, is the successful acquisition of great technology by a large medical device player. In this session, a distinguished panel of executives from leading medical device firms, talk about their goals and objectives and the kinds of technologies they’re looking for and the deals they’re trying to do.

  • "Pharmaceutical giants have been trying to tap into this market for a long time. While several drugs have gained attention over the past few years, only some have shown long-term effectiveness, and they are typically accompanied with an array of side-effects. Anti-obesity medications approach the disorder in various ways, ranging from the suppression of brain receptors that reduce a patient’s appetite to inhibiting enzymes that restrain fat absorption. However, no single solution has had an impact large enough to reverse the growing obesity trend."
    "On the other hand, while current bariatric surgery techniques have demonstrated notable improvements in safety and efficacy compared with years prior, patient aversion to surgical intervention has curbed operation prevalence to less than 1% of suitable obese candidates. In the US alone, of the 20 million Americans that qualified for bariatric surgery in 2012, only 200,000 opted for the surgery."

    So, you have 20 million patients who qualified for surgery in 2012. Yet only 200,000 opted for such a surgical procedure. And pills which we knew have harmful side affects are not what consumers are looking for either. So, if I read between the lines there's 19M 200 thousand patients who qualify for VBLOC who may be interested in less invasive surgery.

    About GlobalData: A one-stop solution for actionable insight into the pharmaceutical and medical device sectors. Together with the best team of researchers, analysts, epidemiologists and consultants, and an unmatched suite of proprietary databases, we provide high-quality, accurate and transparent insight that can help you achieve growth and increase business value.

    Google: Obesity – A Growing Opportunity for the Med-Tech Industry

  • Reply to

    When youve emailed ETRM before...

    by recon1269 Nov 26, 2014 2:10 PM
    pharmaapproved pharmaapproved Nov 26, 2014 2:44 PM Flag

    A few hours to days. Although I have asked repeatedly how obesityweek went and never got a reply.

  • Reply to

    Future of ETRM (per source)

    by adelfig Nov 26, 2014 11:54 AM
    pharmaapproved pharmaapproved Nov 26, 2014 2:42 PM Flag

    lol, your source? I think your source has already told all of us this.

  • pharmaapproved pharmaapproved Nov 25, 2014 5:25 PM Flag

    Up only 100,000 or so which would take 28 days worth of volume to cover them shares. Institutional ownership is up over 2% in the past month.

  • Reply to

    questions regarding approval

    by steelhead111222 Nov 25, 2014 8:32 AM
    pharmaapproved pharmaapproved Nov 25, 2014 9:18 AM Flag

    Also, who discusses finalizing the label with the FDA if it's not going to be approved? Why would the FDA even be wasting their time with this if they weren't going to approve? maybe there's a logical answer. If so I have yet to hear one.

ZNGA
2.695+0.2550(+10.45%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.